| Host |
Mouse |
| Klon |
MMA |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgM kappa |
| Lokalisation |
Cell Membrane |
CD15
|
Diagnostic Biosystems |
MMA |
0.5 ml |
Concentrate |
CE/IVD |
MOB365-05 |
-
|
| Host |
Mouse |
| Klon |
MMA |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgM kappa |
| Lokalisation |
Cell Membrane |
CD15
|
Diagnostic Biosystems |
MMA |
6 ml |
Ready-to-use |
CE/IVD |
PDM127 |
-
|
| Host |
Mouse |
| Klon |
MMA |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Glycoprotein fraction of human lymphocytes |
| Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
1.0 ml |
Concentrate |
CE/IVD |
Z2028ML |
-
|
| Host |
Mouse |
| Klon |
MMA |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma. |
| Verdünnung |
- |
| Isotyp |
IgM |
| Verdünnung |
Glycoprotein fraction of human lymphocytes |
| Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
7 ml |
Ready-to-use |
CE/IVD |
Z2028MP |
-
|
| Host |
Mouse |
| Klon |
MMA |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Glycoprotein fraction of human lymphocytes |
| Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
0.5 ml |
Concentrate |
CE/IVD |
Z2028MS |
-
|
| Host |
Mouse |
| Klon |
MMA |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Glycoprotein fraction of human lymphocytes |
| Lokalisation |
Cell membrane and granular periNucleus |
CD15
|
Zeta Corporation |
MMA |
0.1 ml |
Concentrate |
CE/IVD |
Z2028MT |
-
|
| Host |
Rabbit |
| Klon |
SP189 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Lung, Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human CD16a protein |
| Lokalisation |
Cell Membrane |
CD16a
|
Zytomed Systems GmbH |
SP189 |
0.5 ml |
Concentrate |
RUO |
506-4892 |
-
|
| Host |
Rabbit |
| Klon |
SP189 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Lung, Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human CD16a protein |
| Lokalisation |
Cell Membrane |
CD16a
|
Zytomed Systems GmbH |
SP189 |
1 ml |
Concentrate |
RUO |
506-4894 |
-
|
| Host |
Rat |
| Klon |
YFC118.3 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Rat IgG2b |
| Verdünnung |
Human neutrophils |
CD18 (Integrin beta2, LFA-1 beta2)
|
Zytomed Systems GmbH |
YFC118.3 |
100 µg |
Purified |
RUO |
603-0574 |
-
|
| Host |
Rabbit |
| Klon |
SP110 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD19 |
| Lokalisation |
Cell Membrane |
CD19
|
Zytomed Systems GmbH |
SP110 |
0.5 ml |
Concentrate |
RUO |
520-4102 |
-
|
| Host |
Rabbit |
| Klon |
SP110 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD19 |
| Lokalisation |
Cell Membrane |
CD19
|
Zytomed Systems GmbH |
SP110 |
1 ml |
Concentrate |
RUO |
520-4104 |
-
|
| Host |
Rat |
| Klon |
6D5 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Rat IgG2a |
| Verdünnung |
Human K562 cell line transfected with murine CD19 |
CD19
|
Zytomed Systems GmbH |
6D5 |
250 µg |
Purified |
RUO |
603-0597 |
-
|
| Host |
Rat |
| Klon |
6D5 |
| Format |
Purified |
| Methode |
F, IP, FL |
| Isotyp |
Rat IgG2a |
| Verdünnung |
Human K562 cell line transfected with murine CD19 |
CD19
|
Zytomed Systems GmbH |
6D5 |
100 µg |
Purified |
RUO |
603-0598 |
-
|
| Host |
Rabbit |
| Klon |
RM332 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cell membrane |
CD19
|
Biocare Medical |
RM332 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3270G |
-
|
| Host |
Mouse |
| Klon |
LE-CD19 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptid corresponding to the C-terminus of human CD19 |
| Lokalisation |
Cell membrane, Cytoplasm |
CD19
|
Zytomed Systems GmbH |
LE-CD19 |
0.5 ml |
Concentrate |
RUO |
MSK043-05 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM179 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
1 ml |
Concentrate |
CE/IVD |
Z2481ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM179 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or tonsil |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
7 ml |
Ready-to-use |
CE/IVD |
Z2481MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM179 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
0.5 ml |
Concentrate |
CE/IVD |
Z2481MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM179 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node or tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
A synthetic peptide from the c-terminus of human CD19 protein |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZM179 |
0.1 ml |
Concentrate |
CE/IVD |
Z2481MT |
-
|
| Host |
Rabbit |
| Klon |
ZR212 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
1.0 ml |
Concentrate |
CE/IVD |
Z2547RL |
-
|
| Host |
Rabbit |
| Klon |
ZR212 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
7 ml |
Ready-to-use |
CE/IVD |
Z2547RP |
-
|
| Host |
Rabbit |
| Klon |
ZR212 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
0.5 ml |
Concentrate |
CE/IVD |
Z2547RS |
-
|
| Host |
Rabbit |
| Klon |
ZR212 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Lymph node or tonsil. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human CD19 protein (around aa96-281) |
| Lokalisation |
Cell membrane |
CD19
|
Zeta Corporation |
ZR212 |
0.1 ml |
Concentrate |
CE/IVD |
Z2547RT |
-
|
| Host |
Rabbit |
| Klon |
SP32 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
- |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD20. |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD20
|
Zytomed Systems GmbH |
SP32 |
1 ml |
Concentrate |
RUO |
RBK030 |
-
|
| Host |
Rabbit |
| Klon |
SP32 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
- |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD20. |
| Lokalisation |
Cytoplasm, Cell Membrane |
CD20
|
Zytomed Systems GmbH |
SP32 |
0.5 ml |
Concentrate |
RUO |
RBK030-05 |
-
|
| Host |
Mouse |
| Klon |
L26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Human tonsil B cells |
| Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
1ml |
Concentrate |
CE/IVD |
Z2059ML |
-
|
| Host |
Mouse |
| Klon |
L26 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Human tonsil B cells |
| Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
7 ml |
Ready-to-use |
CE/IVD |
Z2059MP |
-
|
| Host |
Mouse |
| Klon |
L26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Human tonsil B cells |
| Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
0.5 ml |
Concentrate |
CE/IVD |
Z2059MS |
-
|
| Host |
Mouse |
| Klon |
L26 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Human tonsil B cells |
| Lokalisation |
Cell membrane/Cytoplasm |
CD20
|
Zeta Corporation |
L26 |
0.1 ml |
Concentrate |
CE/IVD |
Z2059MT |
-
|
| Host |
Rabbit |
| Klon |
ZR243 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
1 ml |
Concentrate |
RUO |
Z2717RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR243 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
7 ml |
Concentrate |
RUO |
Z2717RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR243 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
0.5 ml |
Concentrate |
RUO |
Z2717RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR243 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil, lymph node |
| Verdünnung |
1:100 - 1:300 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa 197-297) of human MS4A1 protein (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CD20
|
Zeta Corporation |
ZR243 |
0.1 ml |
Concentrate |
RUO |
Z2717RT-R |
-
|
| Host |
Mouse |
| Klon |
1F8 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
1 ml |
Concentrate |
CE/IVD |
MOB028 |
-
|
| Host |
Mouse |
| Klon |
1F8 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB028-01 |
-
|
| Host |
Mouse |
| Klon |
1F8 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:25 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB028-05 |
-
|
| Host |
Mouse |
| Klon |
1F8 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
CD21
|
Diagnostic Biosystems |
1F8 |
6 ml |
Ready-to-use |
CE/IVD |
PDM122 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM75 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
| Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
1 ml |
Concentrate |
CE/IVD |
Z2385ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM75 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
| Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
7 ml |
Ready-to-use |
CE/IVD |
Z2385MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM75 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
| Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
0.5 ml |
Concentrate |
CE/IVD |
Z2385MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM75 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil, lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human CR2 (CD21) protein fragment (around aa 44-196) |
| Lokalisation |
Cell membrane |
CD21
|
Zeta Corporation |
ZM75 |
0.1 ml |
Concentrate |
CE/IVD |
Z2385MT |
-
|
| Host |
Mouse |
| Klon |
2G9 |
| Format |
TCS |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:10 - 1:20 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant human CD21 |
CD21 (EBV Receptor)
|
Zytomed Systems GmbH |
2G9 |
1 ml |
TCS |
RUO |
603-0638 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to C-terminus of human CD22 |
| Lokalisation |
Cell membrane, Cytoplasm |
CD22
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
503-19020 |
-
|
| Host |
Rabbit |
| Klon |
SP104 |
| Format |
Concentrate |
| Reaktivität |
DG |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Human tonsil, spleen, reactive lymph node |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide within Human CD22 aa 250-350 (extracellular) |
| Lokalisation |
Cell Membrane |
CD22
|
Zytomed Systems GmbH |
SP104 |
0.5 ml |
Concentrate |
RUO |
503-4042 |
-
|
| Host |
Rabbit |
| Klon |
SP104 |
| Format |
Concentrate |
| Reaktivität |
DG |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Human tonsil, spleen, reactive lymph node |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide within Human CD22 aa 250-350 (extracellular) |
| Lokalisation |
Cell Membrane |
CD22
|
Zytomed Systems GmbH |
SP104 |
1 ml |
Concentrate |
RUO |
503-4044 |
-
|
| Host |
Rat |
| Klon |
OX-97 |
| Format |
Purified |
| Methode |
FL |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rat IgG1 |
CD22
|
Zytomed Systems GmbH |
OX-97 |
250 µg |
Purified |
RUO |
603-0647 |
-
|
| Host |
Mouse |
| Klon |
BCLAM/1796 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant fragment of human CD22 protein (around aa 52 - 178) |
| Lokalisation |
Cell membrane |
CD22
|
Biocare Medical |
BCLAM/1796 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3229B |
-
|
| Host |
Mouse |
| Klon |
BCLAM/1796 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant fragment of human CD22 protein (around aa 52 - 178) |
| Lokalisation |
Cell membrane |
CD22
|
Biocare Medical |
BCLAM/1796 |
6 ml |
Ready-to-use |
CE/IVD |
API3229AA |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM183 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
| Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
1 ml |
Concentrate |
CE/IVD |
Z2496ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM183 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Lymph node. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human BL-CAM/CD22 protein fragment (around aa52-178) |
| Lokalisation |
Cytoplasm |
CD22
|
Zeta Corporation |
ZM183 |
7 ml |
Ready-to-use |
CE/IVD |
Z2496MP |
-
|